BCL2 and diffuse large B-cell lymphoma: Together, these results demonstrated that BCL-2 expression is inversely regulated by AGK in DLBCL patients, indicating that AGK not only can serve as a biomarker for venetoclax response but also combination of targeting AGK with venetoclax could provide benefit for the treatment of aggressive DLBCL.